We keep the receipts clean: our $PAVS call from Monday opened at 0.4736 and flushed 60% to close at 0.1899. Process over hope.
Let's talk about Spero Therapeutics $SPRO. They won FDA approval for the first oral carbapenem antibiotic for UTIs, partnered with pharma giant GSK. Retail thinks "FDA approval = Lambo." The market thinks "exit liquidity."
$SPRO cratered 23% on the day of its biggest triumph.
In 2,153 historical cases of catalyst-driven gap-downs of 20% or worse, the stock closes green only 43% of the time. The remaining 56% of instances see the selling pressure carry right through to a red close. Amateurs buy the hype; professionals study the distribution.
Sipping coffee while watching retail try to catch a falling knife that literally has FDA approval stamped on it. Journal the lesson.